Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deceptive Thyroid Pathologies: Anaplastic Thyroid Carcinoma Mimics and Clinical Implications.

Head & neck·2026
Same author

Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026
Same author

A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors.

Future oncology (London, England)·2025
Same author

Primary Synovial Sarcoma of the Abdomen and Pelvis.

American journal of clinical oncology·2025
Same author

Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience.

Frontiers in immunology·2025
Same author

Building a pre-surgical multiparametric-MRI-based morphologic, qualitative, semiquantitative, first and high-order radiomic predictive treatment response model for undifferentiated pleomorphic sarcoma to replace RECIST.

Cancer imaging : the official publication of the International Cancer Imaging Society·2025
Same journal

Embolization Followed by Self-Repositioning of a CardioMEMS™ Wireless Pulmonary Artery Hemodynamic Monitoring Sensor Device.

Methodist DeBakey cardiovascular journal·2026
Same journal

Anomalous Origin of the Vertebral Artery from Thyrocervical Trunk: A Rare Anatomical Variant.

Methodist DeBakey cardiovascular journal·2026
Same journal

Intra-atrial Baffling of an Infradiaphragmatic Scimitar Vein without Circulatory Arrest.

Methodist DeBakey cardiovascular journal·2026
Same journal

Value of Myocardial Strain in Assessing Cardiac Masses: A Case Report.

Methodist DeBakey cardiovascular journal·2026
Same journal

Transient Cortical Blindness and Hemi-Spatial Neglect Following Watchman Device Implantation.

Methodist DeBakey cardiovascular journal·2026
Same journal

Hemodynamics of Pericardial Constriction: Role of Echocardiography and Cardiac Catheterization.

Methodist DeBakey cardiovascular journal·2026
See all related articles

Related Experiment Video

Updated: Jun 8, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Systemic therapy for cardiac sarcomas.

Vinod Ravi1, Robert S Benjamin

  • 1The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Methodist Debakey Cardiovascular Journal
|September 14, 2010
PubMed
Summary
This summary is machine-generated.

Cardiac sarcomas, including angiosarcoma, pose risks of local issues and metastasis. Chemotherapy can be effective, contrary to prior beliefs, offering hope against these rare but aggressive tumors.

Related Experiment Videos

Last Updated: Jun 8, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Area of Science:

  • Cardiovascular pathology
  • Oncology
  • Sarcoma research

Background:

  • Cardiac sarcomas present significant clinical challenges, primarily local growth and distant metastasis.
  • Common types include angiosarcoma and high-grade pleomorphic unclassified sarcoma.
  • Pulmonary artery sarcomas represent a distinct clinical-pathological entity.

Purpose of the Study:

  • To summarize the risks associated with cardiac sarcomas.
  • To discuss the efficacy of chemotherapy in treating these tumors.
  • To highlight the limitations of solely focusing on local treatment.

Main Methods:

  • Review of existing literature on cardiac sarcomas.
  • Analysis of clinical presentations and outcomes.
  • Evaluation of treatment responses, including chemotherapy and transplantation.

Main Results:

  • Cardiac sarcomas frequently metastasize, leading to fatal outcomes.
  • Contrary to conventional wisdom, soft-tissue sarcomas can respond to chemotherapy.
  • Local therapies, including cardiac transplantation, are insufficient due to high metastatic rates.

Conclusions:

  • Effective management of cardiac sarcomas requires addressing both local disease and metastatic potential.
  • Chemotherapy shows promise in managing these aggressive tumors.
  • A multimodal approach is crucial for improving patient survival in cardiac sarcoma cases.